ARTICLE | Finance
InterMune, interrupted
Why investors hadn't priced in InterMune's third Esbriet Phase III trial
March 3, 2014 8:00 AM UTC
Given the mixed clinical data that Esbriet pirfenidone has produced in idiopathic pulmonary fibrosis in the past, investors hadn't priced potential results of last week's Phase III ASCEND data into InterMune Inc. (NASDAQ:ITMN). The positive results sent the stock up $23.84 (171%) to $37.80 on Tuesday.
Even though the stock gave back some of its gains, InterMune finished the week up $16.27 (118%) to $30.04...